1. Home
  2. LNG vs NNVC Comparison

LNG vs NNVC Comparison

Compare LNG & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cheniere Energy Inc.

LNG

Cheniere Energy Inc.

HOLD

Current Price

$238.89

Market Cap

50.5B

Sector

Utilities

ML Signal

HOLD

NNVC

NanoViricides Inc.

N/A

Current Price

$1.51

Market Cap

21.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LNG
NNVC
Founded
1983
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.5B
21.2M
IPO Year
1996
2008

Fundamental Metrics

Financial Performance
Metric
LNG
NNVC
Price
$238.89
$1.51
Analyst Decision
Strong Buy
Analyst Count
15
0
Target Price
$294.87
N/A
AVG Volume (30 Days)
2.2M
998.8K
Earning Date
05-07-2026
05-15-2026
Dividend Yield
0.82%
N/A
EPS Growth
69.93
10.00
EPS
N/A
N/A
Revenue
$19,976,000,000.00
N/A
Revenue This Year
$16.48
N/A
Revenue Next Year
$5.89
N/A
P/E Ratio
N/A
N/A
Revenue Growth
27.21
N/A
52 Week Low
$186.20
$0.85
52 Week High
$300.94
$2.23

Technical Indicators

Market Signals
Indicator
LNG
NNVC
Relative Strength Index (RSI) 45.77 48.85
Support Level $232.06 $1.35
Resistance Level $240.94 $1.52
Average True Range (ATR) 6.53 0.15
MACD 0.48 -0.03
Stochastic Oscillator 54.59 14.00

Price Performance

Historical Comparison
LNG
NNVC

About LNG Cheniere Energy Inc.

Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.

About NNVC NanoViricides Inc.

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Share on Social Networks: